US

Products

Chiesi Rare Diseases is committed to developing and commercializing products that meet the needs of healthcare providers and their patients. We deliver our products and associated services to improve the treatment of patients with rare diseases.

We are also dedicated to investing in research and development initiatives that deliver value-added medical solutions.

Ferriprox<sup>®</sup> (deferiprone)
Ferriprox<sup>®</sup> (deferiprone)
Ferriprox® (deferiprone)

WARNING: AGRANULOCYTOSIS AND NEUTROPENIA

  • Ferriprox can cause agranulocytosis that can lead to serious infections and death. Neutropenia may precede the
    development of agranulocytosis.
  • Measure the absolute neutrophil count (ANC) before starting Ferriprox and monitor weekly while on therapy.
  • Interrupt Ferriprox if infection develops and monitor the ANC more frequently.
  • Advise patients taking Ferriprox to report immediately any symptoms indicative of infection.